Skip to main content

Daniel Kelly Benjamin, MD, PhD

Kiser-Arena Distinguished Professor
Professor of Pediatrics
Member in the Duke Clinical Research Institute
Campus mail: 7044 Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27710
Phone: (919) 668-7081

Dr. Danny Benjamin is the Principal Investigator and Chair of the National Institute of Child Health and Human Development’s Pediatric Trials Network. The Network is responsible for designing and leading clinical trials of off-patent medicines in children of all ages across all therapeutic areas. The team has established, or is actively studying, the correct dosing and safety of more than 70 of the most commonly used medicines in children. Each of these trials is conducted under an Investigational New Drug (IND) application with guidance from the Food and Drug Administration for labeling.

The Pediatric Trials Network has directly impacted the healthcare of over 90% of American children.

Signature programs of the Network include clinical trials in premature, term infants, breast feeding mothers, and obese children. Over the past 10 years, Danny’s group has enrolled more premature infants, at more sites, in more clinical trials of off-patent anti-infectives under an IND than all other academic medical centers, pharmaceutical companies, and government agencies in the world, combined.

Danny is recognized by the National Institutes of Health as a premiere mentor and educator. His research program serves as a platform to train students and early career investigators. Danny’s group has a clinical research summer program for high school and college students targeting under-represented minority students, and he is the primary mentor for medical students, residents, subspecialty fellows, and multiple junior faculty. He has been the primary or secondary mentor for 10 faculty who have received career development awards and who have then gone on to secure their own funding.

Danny's service to the community is expressed through his passion for coaching baseball. He has coached over 500 recreation league, travel league, and scholastic baseball games and he is the head coach of Smith Middle School, the 5-year reigning southern conference champions. Danny and his wife own a charitable non-profit that provides athletic and fitness opportunities for disadvantaged school-aged boys and girls.

Education and Training

  • Fellow, Pediatric Infectious Diseases, Pediatrics, Duke University, 1998 - 2001
  • Resident, Pediatrics, Children's Hospital, 1995 - 1998
  • Ph.D., University of North Carolina - Chapel Hill, 2003
  • M.P.H., University of North Carolina - Chapel Hill, 2001
  • M.D., University of Virginia, 1995

Selected Grants and Awards

Publications

Puia-Dumitrescu, Mihai, P Brian Smith, Jian Zhao, Angela Soriano, Elizabeth H. Payne, Barrie Harper, Ellen Bendel-Stenzel, et al. “Dosing and Safety of Off-label Use of Caffeine Citrate in Premature Infants.” J Pediatr 211 (August 2019): 27-32.e1. https://doi.org/10.1016/j.jpeds.2019.04.028.

Full Text

Zimmerman, Kanecia O., Daniel K. Benjamin, and Mara L. Becker. “Neonatal Therapeutics: Considerations for Dosing.” Am J Perinatol 36, no. S 02 (July 2019): S18–21. https://doi.org/10.1055/s-0039-1691772.

Full Text

Gerhart, Jacqueline G., Kevin M. Watt, Andrea Edginton, Kelly C. Wade, Sara N. Salerno, Daniel K. Benjamin, P Brian Smith, et al. “Physiologically-Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants.” In Cpt Pharmacometrics Syst Pharmacol, 8:500–510, 2019. https://doi.org/10.1002/psp4.12414.

Full Text

Smith, P Brian, C Michael Cotten, Mark L. Hudak, Janice E. Sullivan, Brenda B. Poindexter, Michael Cohen-Wolkowiez, Felix Boakye-Agyeman, et al. “Rifampin Pharmacokinetics and Safety in Preterm and Term Infants.” Antimicrob Agents Chemother 63, no. 6 (June 2019). https://doi.org/10.1128/AAC.00284-19.

Full Text

Greenberg, Rachel G., Sreepriya Gayam, Destiny Savage, Andrew Tong, Daniel Gorham, Ari Sholomon, Reese H. Clark, et al. “Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants.” J Pediatr 208 (May 2019): 134-140.e2. https://doi.org/10.1016/j.jpeds.2018.11.043.

Full Text

Watt, Kevin M., Christoph P. Hornik, Stephen J. Balevic, Gratias Mundakel, C Michael Cotten, Barrie Harper, Daniel K. Benjamin, et al. “Pharmacokinetics of ticarcillin-clavulanate in premature infants.” Br J Clin Pharmacol 85, no. 5 (May 2019): 1021–27. https://doi.org/10.1111/bcp.13882.

Full Text

Rivera-Chaparro, Nazario D., Jessica Ericson, Huali Wu, P Brian Smith, Reese H. Clark, Daniel K. Benjamin, Michael Cohen-Wolkowiez, and Rachel G. Greenberg. “Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records.” Pediatr Infect Dis J 38, no. 2 (February 2019): e26–28. https://doi.org/10.1097/INF.0000000000002045.

Full Text

Cohen-Wolkowiez, Michael, and Daniel K. Benjamin. “Development of Therapeutics for Children-A Tricky Balancing Act.” Jama Pediatr 173, no. 1 (January 1, 2019): 18–19. https://doi.org/10.1001/jamapediatrics.2018.4026.

Full Text

Autmizguine, Julie, P Brian Smith, Kristi Prather, Catherine Bendel, Girija Natarajan, Margarita Bidegain, David A. Kaufman, et al. “Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants.” J Antimicrob Chemother 73, no. 12 (December 1, 2018): 3482–87. https://doi.org/10.1093/jac/dky353.

Full Text

Puia-Dumitrescu, Mihai, Olivia M. Bretzius, Nia Brown, James A. Fitz-Henley, Rebecca Ssengonzi, Caroline S. Wechsler, Keyaria D. Gray, et al. “Evaluation of Gentamicin Exposure in the Neonatal Intensive Care Unit and Hearing Function at Discharge.” J Pediatr 203 (December 2018): 131–36. https://doi.org/10.1016/j.jpeds.2018.07.101.

Full Text

Pages